Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Inclusion criteria

* Ability to give informed consent * Treatment- naïve patients with active, subfoveal, exudative AMD * Patients with visual acuity of 20/40-20/320 in the study eye * Subfoveal choroidal neovascularization (CNV) must be at least 50% of the total lesion size Total area of lesion components other that CNV must be less than 50% of the total lesion size * The lesion must be \< 5400microns in greatest linear dimension (GLD) * Lesion size \< 10 DA * Occult with no classic CNV lesions must have presumed recent disease progression: 1. Blood associated with the lesion at baseline 2. Loss of visual acuity in the previous 3 months: a: \> 5 letter loss (ETDRS equivalent) or b: 2 or more lines using a snellen or equivalent chart 3. \> 10% increase in GLD as assessed by fluorescein angiography in the previous 3 months * Previous treatment for CNV with anti-VEGF agents, intraocular steroids and/or Photodynamic therapy with Visudyne® in the study eye * Geographic atrophy or fibrosis in the study eye * Intraocular surgery within 6 weeks of enrollment * Subretinal hemorrhage \> 50% of the total lesion * Patients with intraocular pressure greater than 30 mm/Hg on 2 pressure-lowering medications * Patients with severe disciform scarring. * Inability to make study visits * Advanced glaucoma * Allergies to porfins or a known hypersensitivity to any component of Visudyne® * Patients with porphyria * Pregnancy or lactation